Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials
The increased research activity aiming at improved delivery of pharmaceutical molecules indicates the expansion of the field. An efficient therapeutic delivery approach is based on the optimal choice of drug-carrying vehicle, successful targeting, and payload release enabling the site-specific accum...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/17/9149 |
id |
doaj-f6ca6aabaf144c96848c6ff4ffdbb4a8 |
---|---|
record_format |
Article |
spelling |
doaj-f6ca6aabaf144c96848c6ff4ffdbb4a82021-09-09T13:46:46ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-08-01229149914910.3390/ijms22179149Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical TrialsDenis V. Voronin0Anatolii A. Abalymov1Yulia I. Svenskaya2Maria V. Lomova3Science Medical Center, Saratov State University, Astrakhanskaya St. 83, 410012 Saratov, RussiaScience Medical Center, Saratov State University, Astrakhanskaya St. 83, 410012 Saratov, RussiaScience Medical Center, Saratov State University, Astrakhanskaya St. 83, 410012 Saratov, RussiaScience Medical Center, Saratov State University, Astrakhanskaya St. 83, 410012 Saratov, RussiaThe increased research activity aiming at improved delivery of pharmaceutical molecules indicates the expansion of the field. An efficient therapeutic delivery approach is based on the optimal choice of drug-carrying vehicle, successful targeting, and payload release enabling the site-specific accumulation of the therapeutic molecules. However, designing the formulation endowed with the targeting properties in vitro does not guarantee its selective delivery in vivo. The various biological barriers that the carrier encounters upon intravascular administration should be adequately addressed in its overall design to reduce the off-target effects and unwanted toxicity in vivo and thereby enhance the therapeutic efficacy of the payload. Here, we discuss the main parameters of remote-controlled drug delivery systems: (i) key principles of the carrier selection; (ii) the most significant physiological barriers and limitations associated with the drug delivery; (iii) major concepts for its targeting and cargo release stimulation by external stimuli in vivo. The clinical translation for drug delivery systems is also described along with the main challenges, key parameters, and examples of successfully translated drug delivery platforms. The essential steps on the way from drug delivery system design to clinical trials are summarized, arranged, and discussed.https://www.mdpi.com/1422-0067/22/17/9149drug delivery systemsactive targeting in vivophysiological barriersremote navigationmagnetic fieldselectric fields |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Denis V. Voronin Anatolii A. Abalymov Yulia I. Svenskaya Maria V. Lomova |
spellingShingle |
Denis V. Voronin Anatolii A. Abalymov Yulia I. Svenskaya Maria V. Lomova Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials International Journal of Molecular Sciences drug delivery systems active targeting in vivo physiological barriers remote navigation magnetic fields electric fields |
author_facet |
Denis V. Voronin Anatolii A. Abalymov Yulia I. Svenskaya Maria V. Lomova |
author_sort |
Denis V. Voronin |
title |
Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials |
title_short |
Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials |
title_full |
Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials |
title_fullStr |
Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials |
title_full_unstemmed |
Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials |
title_sort |
key points in remote-controlled drug delivery: from the carrier design to clinical trials |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2021-08-01 |
description |
The increased research activity aiming at improved delivery of pharmaceutical molecules indicates the expansion of the field. An efficient therapeutic delivery approach is based on the optimal choice of drug-carrying vehicle, successful targeting, and payload release enabling the site-specific accumulation of the therapeutic molecules. However, designing the formulation endowed with the targeting properties in vitro does not guarantee its selective delivery in vivo. The various biological barriers that the carrier encounters upon intravascular administration should be adequately addressed in its overall design to reduce the off-target effects and unwanted toxicity in vivo and thereby enhance the therapeutic efficacy of the payload. Here, we discuss the main parameters of remote-controlled drug delivery systems: (i) key principles of the carrier selection; (ii) the most significant physiological barriers and limitations associated with the drug delivery; (iii) major concepts for its targeting and cargo release stimulation by external stimuli in vivo. The clinical translation for drug delivery systems is also described along with the main challenges, key parameters, and examples of successfully translated drug delivery platforms. The essential steps on the way from drug delivery system design to clinical trials are summarized, arranged, and discussed. |
topic |
drug delivery systems active targeting in vivo physiological barriers remote navigation magnetic fields electric fields |
url |
https://www.mdpi.com/1422-0067/22/17/9149 |
work_keys_str_mv |
AT denisvvoronin keypointsinremotecontrolleddrugdeliveryfromthecarrierdesigntoclinicaltrials AT anatoliiaabalymov keypointsinremotecontrolleddrugdeliveryfromthecarrierdesigntoclinicaltrials AT yuliaisvenskaya keypointsinremotecontrolleddrugdeliveryfromthecarrierdesigntoclinicaltrials AT mariavlomova keypointsinremotecontrolleddrugdeliveryfromthecarrierdesigntoclinicaltrials |
_version_ |
1717760250141999104 |